It actually happened. On April 22, 2026, the Department of Justice and the DEA moved cannabis off Schedule I for the first time in over fifty years. The lock came off — partially. State-licensed medical cannabis is now Schedule III. 280E goes away for that slice of the industry overnight. The DEA set June 29, 2026 as the date for an evidentiary hearing on whether the rest of the industry follows. And the Supreme Court is one ruling away from giving medical cannabis patients their gun rights back.
This is the Cannabis Legalization News weekly recap for April 26, 2026. Ten stories. One brutal week of federal change layered on a state-by-state landscape that is anything but uniform. Here is what happened, what it means, and what to watch.
👉 Prefer to watch instead of read? The full breakdown is on this week’s Cannabis Legalization News show on YouTube.
Story 1: DOJ Reschedules State-Licensed Medical Cannabis to Schedule III
Acting Attorney General Todd Blanche signed an order — and the DEA published a final order taking effect that same day — moving two specific buckets of cannabis from Schedule I to Schedule III: FDA-approved drug products containing marijuana, and marijuana subject to a state-issued license to manufacture, distribute, or dispense for medical purposes only.
Recreational cannabis stays in Schedule I. So do bulk marijuana, marijuana extract, delta-9 distillate, and synthetically derived THC outside the licensed medical lane. This is a bifurcated rescheduling — and that bifurcation is the legal story of 2026.
Smart Approaches to Marijuana said within hours that it would sue. Expect APA challenges in multiple circuits over the coming months. None of those challenges are likely to obtain a stay, but they will shape the contours of the Schedule III lane.
Story 2: 280E Cracks Open — Treasury Asked to Consider Retroactive Relief
Section 280E of the Internal Revenue Code denies ordinary business deductions for any business “trafficking” in a Schedule I or II controlled substance. Because state-licensed medical cannabis is no longer in Schedule I or II, the statutory hook for 280E goes away as of April 22, 2026 for that activity. Effective tax rates that were running 60 to 80 percent should drop dramatically for medical-licensed operators. Adult-use is unchanged.
The DOJ order goes one step further and directs Treasury to consider retrospective relief — i.e., refunds — for state-licensed medical operators on prior years. Treasury has not committed to a path yet. Cannabis operators should not amend returns until guidance lands. They should preserve every workpaper from 2023, 2024, and 2025.
Story 3: DEA Sets June 29 Hearing on Full Rescheduling
The same DOJ order resets the broader rescheduling proceeding that has been stalled since 2024. A new evidentiary hearing begins June 29, 2026, and the question on the table is whether all marijuana — including adult-use — moves to Schedule III. If the timeline holds, a final rule could be on the books before year-end. Litigation from prohibitionist groups will almost certainly extend the calendar into 2027.
The political signal is clear: medical first, adult-use second. The administration is letting the safest version of the policy run for a few months before expanding it.
Story 4: Pennsylvania’s 4/20 Hearing Moves the Calendar
On April 20, Pennsylvania Democrats held a public testimony hearing on three competing legalization vehicles — SB 120, HB 20, and HB 1735. Public support sits at 56% in favor and 37% against per a February 2026 survey. Governor Shapiro has signaled he would sign a workable bill. The fight is about the ownership model — state-store monopoly versus private licensure — and how social equity slots in.
None of the bills have had a committee hearing yet. The 4/20 testimony day is a sign the calendar is moving, not a vote. PA is the largest remaining un-legalized state in the Northeast and Mid-Atlantic.
Story 5: Virginia’s Two Retail Bills — Spanberger Picks the Launch Date
In February, both chambers of the Virginia legislature passed competing retail cannabis frameworks. HB 642 from the House targets a November 1, 2026 retail launch. SB 542 from the Senate pushes it to January 1, 2027. Governor Abigail Spanberger has signaled she is likely to sign a unified version.
While the legislature wrangles, the M&A market already moved: Cannabist Co. closed a $130M sale of its Virginia medical operation in April. Adult-use Virginia is being priced in regardless of which date wins.
Story 6: Ohio’s SB 56 Rollback — When the Legislature Eats a Voter Initiative
Ohio voters legalized adult-use cannabis in November 2023. In 2026, the Ohio legislature passed SB 56, which lowers some THC potency caps, re-criminalizes specific conduct that the voter initiative had decriminalized, and strips out employment-protection language for off-duty cannabis use.
SB 56 is the case study. Ballot initiatives can be gutted by the next legislature unless the language is locked in at constitutional level. Existing Ohio operators have a real compliance hit on labels, products, and employment policies. Advocates are organizing to push the initiative back to constitutional amendment status.
Story 7: Rhode Island’s Residency Wall Falls
On April 8, U.S. District Judge Melissa DuBose entered a preliminary injunction blocking the Rhode Island Cannabis Control Commission from running its scheduled May lottery for up to 24 retail dispensary licenses. Three federal lawsuits filed by out-of-state applicants challenge Rhode Island’s rule that 51% of any cannabis licensee must be owned by a state resident.
Plaintiffs argued the residency requirement violates the dormant Commerce Clause — and Judge DuBose found they were likely to win on the merits. 97 applicants are stuck in limbo. This is the same dormant Commerce Clause argument that has already taken down residency rules in Maine and New York. The streak continues.
Name That Strain: Toad Venom
Spring 2026 critic pick on Leafly’s seasonal review. Toad Venom (Animal Face × Sin Mintz) is a caryophyllene-forward hybrid with myrcene and limonene support. Earthy, peppery, with citrus on the back end. Tart hybrid expression that runs dawn-to-dusk.
Strong contender for medical menus precisely because of the caryophyllene profile, which interacts with CB2 receptors. Very on-theme for the week medical cannabis became Schedule III.
Story 8: PharmaCann Exits Colorado — 132 Layoffs and the MSO Playbook
Chicago-based MSO PharmaCann is closing its Denver cultivation operation by May 20 and laying off 132 workers. The shutdown comes only months after PharmaCann’s Colorado acquisition. The company joins Vireo Growth (which recently absorbed Eaze without picking up cultivation), Sunderstorm (Lime), and Wyld (Grön) in 2026’s consolidation wave.
The message inside the consolidation wave is straightforward: wholesale flower at retail-distressed prices is cheaper than running your own grow. The MSO playbook for 2026 is “own brand, own retail, outsource cultivation.”
Story 9: SCOTUS US v. Hemani — Guns + Weed at the Supreme Court
The Supreme Court heard oral argument on March 2 in United States v. Hemani, a Fifth Circuit case challenging 18 U.S.C. § 922(g)(3) — the federal ban on firearm possession by “an unlawful user of any controlled substance.” The justices, across the ideological spectrum, sounded skeptical that a categorical ban survives Bruen-era Second Amendment analysis. A decision is expected by late June.
Justice Barrett’s hypothetical — does the wife who borrows her husband’s Ambien lose her gun rights? — telegraphs the Court’s discomfort with how broad “unlawful user” is. Combined with Story 1, the Hemani decision could mean a medical cannabis patient in a state-legal program is no longer an “unlawful user” at all. Quietly the biggest Second Amendment restoration story of the decade.
Story 10: Q1 2026 Cannabis Sales = $6.5B / 4/20 +47%
U.S. legal cannabis sales topped $2.3 billion in March, just under $6.6 billion for Q1 2026. 4/20 transactions jumped 46.6% year-over-year and dollar volume jumped 46.9%, driven heavily by newer-market states like Ohio, Maryland, and Missouri (which set a new monthly recreational record at $131M). Illinois moved 4.67M units in March and remains the #5 market behind California, Michigan, New York, and Massachusetts.
Demand is fine. The problem is wholesale price compression, 280E (now partially solved on the medical side), and capital cost. Newer markets are supplying the growth. Mature markets are getting more efficient, not bigger.
Final Thought
The federal lock came off — partially. Medical state-licensed cannabis is Schedule III as of Wednesday, 280E goes away for that slice, the DEA has set June 29 to argue about whether the rest of the industry follows, and the Supreme Court is one ruling away from giving medical patients their gun rights back. At the same time, operators are still cutting cultivation capacity, voters and legislatures are still fighting tug-of-war over rollbacks, and the licensing maze in places like Rhode Island is still in court.
The federal ceiling is finally moving. The state floor is uneven. Demand is concentrating in newer markets. The smart operator this week is the one running medical revenue separately on the books, who knows their state-license language word-for-word, and has a 280E refund-and-amendment strategy ready to go the day Treasury moves.
Watch the full show
👉 This week’s Cannabis Legalization News show on YouTube — full breakdown of all 10 stories, Name That Strain, and the Final Thought.
Want the weekly recap in your inbox? Subscribe to the CLN newsletter — free, spicy, actually useful.
Cannabis Legalization News is a weekly cannabis law, policy, and business show hosted by Thomas Howard. Sponsored by Collateral Base — strategy and execution for cannabis licensing applications and dispensary operations.
